Abstract
HER-2/neu status and t-PA, u-PA, and PAI-1 cytosol content were evaluated in 88 primary breast cancer patients to determine the relationships between these parameters. HER-2/neu was amplified in 24% (20/84) of tumor samples and overexpressed in 28% (14/50). In the overall series, median t-PA, u-PA and PAT-1 contents, measured by the enzyme-linked immunoassay (ELISA), resulted in 1.7, 1.1 and 1.0 ng/mg cytosol protein (cyt prot), respectively. HER-2/neu overexpressed cases showed higher u-PA levels than those normally expressed whereas t-PA and PAI-1 levels did not vary in HER-2/neu altered and non altered cases. The t-PA levels did not differ in cases with or without HER-2/neu alterations, when separately considering the node-negative and node-positive cases. A significant relationship between t-PA levels and HER-2/neu alterations was observed only in the ER+ tumors: t-PA levels were lower in amplified and overexpressed cases (1.4 versus 2.5 ng/mg cyt prot in amplified and single copy gene, respectively; 1.6 versus 2.3 ng/mg cyt prot in overexpressed and normally expressed cases, respectively). Therefore, t-PA and HER-2/neu could provide additional prognostic information for ER-negative patients.
| Original language | English |
|---|---|
| Pages (from-to) | 473-477 |
| Number of pages | 5 |
| Journal | International Journal of Oncology |
| Volume | 5 |
| Issue number | 3 |
| Publication status | Published - 1994 |
Fingerprint
Keywords
- Breast cancer
- Fibrinolytic factors
- HER-2/neu
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
HER-2/neu and fibrinolytic factors in human breast cancer. / Tommasi, S.; Rella, C.; Giannella, C.; Quaranta, M.; Schittulli, F.; Paradiso, A.; Coviello, M.; De Lena, M.
In: International Journal of Oncology, Vol. 5, No. 3, 1994, p. 473-477.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - HER-2/neu and fibrinolytic factors in human breast cancer
AU - Tommasi, S.
AU - Rella, C.
AU - Giannella, C.
AU - Quaranta, M.
AU - Schittulli, F.
AU - Paradiso, A.
AU - Coviello, M.
AU - De Lena, M.
PY - 1994
Y1 - 1994
N2 - HER-2/neu status and t-PA, u-PA, and PAI-1 cytosol content were evaluated in 88 primary breast cancer patients to determine the relationships between these parameters. HER-2/neu was amplified in 24% (20/84) of tumor samples and overexpressed in 28% (14/50). In the overall series, median t-PA, u-PA and PAT-1 contents, measured by the enzyme-linked immunoassay (ELISA), resulted in 1.7, 1.1 and 1.0 ng/mg cytosol protein (cyt prot), respectively. HER-2/neu overexpressed cases showed higher u-PA levels than those normally expressed whereas t-PA and PAI-1 levels did not vary in HER-2/neu altered and non altered cases. The t-PA levels did not differ in cases with or without HER-2/neu alterations, when separately considering the node-negative and node-positive cases. A significant relationship between t-PA levels and HER-2/neu alterations was observed only in the ER+ tumors: t-PA levels were lower in amplified and overexpressed cases (1.4 versus 2.5 ng/mg cyt prot in amplified and single copy gene, respectively; 1.6 versus 2.3 ng/mg cyt prot in overexpressed and normally expressed cases, respectively). Therefore, t-PA and HER-2/neu could provide additional prognostic information for ER-negative patients.
AB - HER-2/neu status and t-PA, u-PA, and PAI-1 cytosol content were evaluated in 88 primary breast cancer patients to determine the relationships between these parameters. HER-2/neu was amplified in 24% (20/84) of tumor samples and overexpressed in 28% (14/50). In the overall series, median t-PA, u-PA and PAT-1 contents, measured by the enzyme-linked immunoassay (ELISA), resulted in 1.7, 1.1 and 1.0 ng/mg cytosol protein (cyt prot), respectively. HER-2/neu overexpressed cases showed higher u-PA levels than those normally expressed whereas t-PA and PAI-1 levels did not vary in HER-2/neu altered and non altered cases. The t-PA levels did not differ in cases with or without HER-2/neu alterations, when separately considering the node-negative and node-positive cases. A significant relationship between t-PA levels and HER-2/neu alterations was observed only in the ER+ tumors: t-PA levels were lower in amplified and overexpressed cases (1.4 versus 2.5 ng/mg cyt prot in amplified and single copy gene, respectively; 1.6 versus 2.3 ng/mg cyt prot in overexpressed and normally expressed cases, respectively). Therefore, t-PA and HER-2/neu could provide additional prognostic information for ER-negative patients.
KW - Breast cancer
KW - Fibrinolytic factors
KW - HER-2/neu
UR - http://www.scopus.com/inward/record.url?scp=0028029396&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028029396&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0028029396
VL - 5
SP - 473
EP - 477
JO - International Journal of Oncology
JF - International Journal of Oncology
SN - 1019-6439
IS - 3
ER -